About cellectis sa - CLLS
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
CLLS At a Glance
Cellectis SA
8, rue de la Croix Jarry
Paris, Ile-de-France 75013
| Phone | 33-1-81-69-16-00 | Revenue | 73.17M | |
| Industry | Pharmaceuticals: Major | Net Income | -67,802,146.47 | |
| Sector | Health Technology | 2025 Sales Growth | 76.615% | |
| Fiscal Year-end | 12 / 2026 | Employees | 229 | |
| View SEC Filings |
CLLS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 6.633 |
| Price to Book Ratio | 6.398 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -19.48 |
| Enterprise Value to Sales | 5.42 |
| Total Debt to Enterprise Value | 0.302 |
CLLS Efficiency
| Revenue/Employee | 319,540.258 |
| Income Per Employee | -296,079.242 |
| Receivables Turnover | 2.89 |
| Total Asset Turnover | 0.202 |
CLLS Liquidity
| Current Ratio | 1.621 |
| Quick Ratio | 1.621 |
| Cash Ratio | 1.432 |
CLLS Profitability
| Gross Margin | 72.499 |
| Operating Margin | -55.324 |
| Pretax Margin | -102.345 |
| Net Margin | -92.658 |
| Return on Assets | -18.729 |
| Return on Equity | -65.53 |
| Return on Total Capital | -34.628 |
| Return on Invested Capital | -34.435 |
CLLS Capital Structure
| Total Debt to Total Equity | 157.968 |
| Total Debt to Total Capital | 61.235 |
| Total Debt to Total Assets | 36.171 |
| Long-Term Debt to Equity | 134.04 |
| Long-Term Debt to Total Capital | 51.96 |